HIGHLIGHTS
- who: Pierre-Michel Llorca from the University Hospital Center, EA , University Clermont Auvergne, Clermont-Ferrand, France have published the research: Baseline results from the European non-interventional Antipsychotic Long acTing injection in schizOphrenia (ALTO) study, in the Journal: (JOURNAL)
- what: The aim of the Antipsychotic Long-acTing injection in schizOphrenia (ALTO) study was to describe utilization of firstand second-generation (FGA- and SGA-) LAI antipsychotic treatments, and the sociodemographic and clinical characteristics of patients with schizophrenia from different countries in Europe, as well as the characteristics of their prescribing physicians. Although 58.9% of the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.